Skip to content
MarketScale
Demo
‹ Back to IndustriesHealthcare

Driving Business Growth in B2B Marketing: The Game-Changing Impact of the Creator Economy

B2B brands in the healthcare industry are increasingly leveraging creator economy partnerships to build credibility and drive revenue growth. The article explores how thought leaders and content creators can serve as strategic assets in crowded B2B marketplaces. Creator-led strategies are emerging as a differentiator for healthcare organizations seeking authentic audience engagement.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Experts Talk on MarketScale.

By Experts Talk · BlitzmetricsCreator EconomyDavid KempDennis Yu
Share

Key takeaways

01

B2B healthcare brands are partnering with creators to establish credibility in competitive markets.

02

The creator economy is reshaping how B2B companies approach demand generation and revenue growth.

03

Authentic creator content can accelerate trust-building with healthcare decision-makers and buyers.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Influencer marketing is no longer just for consumer brands. In a report titled Influencing Business: The Global Rise of B2B Influencer Marketing, Ogilvy estimates that the global market size has expanded over 20 times since 2016! And with the creator economy projected to reach $500 billion by 2027, businesses are taking note. Social platforms like YouTube, Instagram, and TikTok, boasting nearly 5 billion monthly active users, have fueled this rise of the creator economy. The question is, how can the B2B marketing sector leverage this trend to build trust and drive business impact?

And with the creator economy projected to reach $500 billion by 2027, businesses are taking note.

In the latest episode of Experts Talk, host Gabrielle Bejarano dives into this topic with guests David Kemp, Healthcare Lead at MarketScale, and Dennis Yu, CTO of BlitzMetrics. They explore the evolving landscape of influencer marketing and its growing importance in the B2B marketing sector.

Key discussion points include:

– The exponential growth and potential of influencer marketing in B2B.

– The importance of selecting credible influencers to build trust.

– How leveraging employee influencers can be a game-changer.

About the Speakers

David Kemp's career spans from coaching college basketball to aiding major healthcare systems with ICD-10 transitions. Kemp now hosts the Highway to Health podcast series and leads the healthcare vertical at MarketScale.

Dennis Yu is the CEO of BlitzMetrics, a digital marketing company that collaborates with schools to train young adults in the field. He has extensive experience in managing high-profile campaigns for clients like The Golden State Warriors and Nike, and is also an internationally recognized lecturer who has spoken at over 730 events across 17 countries.

Experts Talk

Part of this channel

Experts Talk

Industry experts debate the ideas that drive B2B decisions.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

ET
Experts Talk

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

The FDA’s interchangeable biosimilar pathway is moving from a one-off insulin milestone to a repeatable playbook for pharmacy-level substitution, with Wezlana (ustekinumab-auub) approved as interchangeable to Stelara in late 2023 and a first interchangeable biosimilar to golimumab reported in September 2026. Evidence from a JAMA Health Forum economic evaluation cited by Podiatry Today found that insulin glargine interchangeability in November 2021 was followed by an immediate jump of more than 47,000 prescriptions for Semglee and insulin glargine-yfgn, suggesting the designation itself can change dispensing behavior. For hospitals, health systems, and payers, the operational consequence shows up less in the FDA letter and more in formulary design, NDC-level claims logic, pharmacy notification requirements that vary by state, and the inventory and education workflows that make substitution predictable instead of chaotic.

  • 01Interchangeability is a workflow change, not a clinical debate. The systems that decide spend are NDC mapping, e-prescribe defaults, and pharmacy switch rules governed by state law.
  • 02The pipeline is widening beyond diabetes. Wezlana’s interchangeability to Stelara (Healthcare Purchasing News) and a newly reported interchangeable golimumab biosimilar (Journal of Healthcare Management/AJN via Ovid) signal more specialty and infusion-adjacent categories will face pharmacy-level substitution decisions.

Sep 2, 2026

More nurses did not lift safety culture scores in a 205-hospital analysis

More nurses did not lift safety culture scores in a 205-hospital analysis

A 2026 analysis in the Journal of Hospital Management and Health Policy combined 2021–2022 HSOPC results with AHA, HCRIS, and AHRF data across 205 hospitals and reported that small increases in nurse and physician staffing lined up with slightly lower “percent positive” patient safety culture scores in several dimensions. According to the Journal of Healthcare Management abstract hosted on Ovid, the study described a 2% decrease in positive staffing perceptions with β=−0.02 per additional nurse FTE and a −0.01 change in perceived reporting of patient safety events per additional nurse, while additional physician staffing was associated with −0.01 changes in perceptions of communication openness and organizational learning, and joint ventures were associated with a −0.03 change in perceptions of management support for safety (all p<0.05). The operational read is that adding headcount by itself does not ensure stronger safety-culture signals; hospitals also need the workflows that turn observations into closed-loop fixes, from “just culture” reporting expectations to facilities work-order follow-through, as described by Sentara Health leaders in Chief Healthcare Executive and by Health Facilities Management’s environment-of-care guidance. For health system operators, the near-term consequence shows up in how HSOPC survey targets connect to leader scorecards, rounding programs, digital reporting tools, and joint-venture governance, especially where staffing growth is driven by complexity and handoffs.

  • 01If HSOPC “percent positive” scores are a board KPI, staffing increases can move in the opposite direction unless reporting and learning loops scale too. The study’s negative coefficients are small, but they signal a measurement risk during growth.
  • 02Facilities and clinical safety cultures converge in the same pipeline: observation, reporting, triage, work order, verification. HFM Magazine’s door-lock example is the same system problem as event reporting, it is throughput and closure, not awareness.
  • 03Joint ventures can add operational complexity that dilutes perceived management support for safety. That belongs in JV governance charters and integration playbooks, not only in finance models.

Sep 1, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

ET
Experts Talk
Company

For Healthcare teams

See how Healthcare teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›Marketing Tech›
Keep exploring

More from Healthcare

Healthcare hubMore expert Healthcare coverage.Explore →Executive Thought LeadershipPut clinical leaders on the record.Explore →CooperVisionMedical device storytelling.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512